BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new ...

Forecast for 2025 For the current fiscal year, Dräger expects an increase in net sales of 1.0 to 5.0 percent (net of currency effects) and an EBIT margin of 3.5 to 6.5 percent. The expected EBIT ...

PHYRAGO™ Represents the First and Only Improved Version of SPRYCEL® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / Handa ...

Cellev8's Brand Expands Beyond Consumers  WELLINGTON, FLORIDA / ACCESSWIRE / January 15, 2025 / Cellev8 Nutrition Inc., a leader in natural health supplements, is proud to announce an exclusive ...

Comprehensive Gratis Report Featuring Profiles and Client Engagement Ratings for 260 HIT Consulting and Advisory Firms TAMPA, FLORIDA / ACCESSWIRE / January 15, 2025 / Black Book Research announces ...

NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced the ...

Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design ...

Innovative Research Confirms Accuracy and Reliability of Online ADHD Diagnostic Evaluation GRAND RAPIDS, MICHIGAN / ACCESSWIRE / January 15, 2025 / Mentavi Health, a leader in evidence-based mental ...

Oxford Drug Design, the Oxford-based AI drug discovery company, has today announced additional in vivo validation for its first-in-class approach against cancer as the Company continues to apply its ...

SAN DIEGO, CALIFORNIA / ACCESSWIRE / January 15, 2025 / Rancho BioSciences, the premier tech-enabled data science partner for biopharma, headquartered in San Diego, California, is excited to announce ...

FORT LAUDERDALE, FL / ACCESSWIRE / January 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of ...

Osteosarcoma is a type of aggressive bone cancer that most commonly affects children and young adults between the ages of 10 and 20, during times of rapid bone growth. Although rare, it has a ...